Fidelity Investments’s Tonix Pharmaceuticals TNXP Stock Holding History

Fidelity Investments’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.9K	Buy	1,738 +234	+16%	+$3.6K	﹤0.01%	4443
2025 Q4	$23.5K	Sell	1,504 -43,962	-97%	-$810K	﹤0.01%	4406
2025 Q3	$1.1M	Buy	45,466 +32,713	+257%	+$1.21M	﹤0.01%	2766
2025 Q2	$459K	Buy	+12,753	New	+$334K	﹤0.01%	2992
2025 Q1	–	Hold	0	–	–	–	5671
2024 Q4	–	Hold	0	–	–	–	5809
2024 Q3	–	Hold	0	–	–	–	5727
2024 Q1	–	Hold	0	–	-$10	–	5714
2023 Q4	–	Hold	0	–	–	–	5325
2023 Q3	–	Hold	0	–	–	–	5240
2023 Q1	–	Hold	0	–	–	–	5521
2022 Q4	–	Hold	0	–	–	–	5593
2022 Q3	–	Hold	0	–	-$3K	–	5401
2022 Q2	–	Hold	0	–	–	–	4496
2022 Q1	–	Hold	0	–	–	–	4453
2021 Q4	–	Hold	0	–	–	–	4920
2021 Q3	–	Hold	0	–	–	–	5021
2021 Q2	–	Hold	0	–	–	–	4870

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JHC

Jones Hill Capital New York $466M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Fidelity Investments's TNXP Position: Q1 2026 in Review

Fidelity Investments increased its Tonix Pharmaceuticals (TNXP) stake by 16% in Q1 2026, buying an estimated $3.6K and bringing the position to 1,738 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4443.

Fidelity Investments first reported a position in TNXP in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.1M in Q3 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

Fidelity Investments held 1,738 shares of Tonix Pharmaceuticals worth $23.9K as of Q1 2026.
Fidelity Investments bought 234 Tonix Pharmaceuticals shares in Q1 2026, an estimated $3.6K.
Tonix Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4443 holding.
Fidelity Investments first reported a position in Tonix Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
Fidelity Investments's Tonix Pharmaceuticals position peaked at $1.1M in Q3 2025.
81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.